Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 3/20 | 0.53 |
| ▸ | CACNB4 | O00305 | 2/20 | 0.53 |
| ▸ | CACNA1A | O00555 | 2/20 | 0.53 |
| ▸ | CACNG3 | O60359 | 2/20 | 0.53 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.53 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.53 |
| ▸ | CACNB3 | P54284 | 2/20 | 0.53 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.53 |
| ▸ | CACNG7 | P62955 | 2/20 | 0.53 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.53 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.53 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.53 |
| ▸ | CACNG1 | Q06432 | 2/20 | 0.53 |
| ▸ | CACNB2 | Q08289 | 2/20 | 0.53 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.53 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.53 |
| ▸ | CACNA1E | Q15878 | 2/20 | 0.53 |
| ▸ | CACNA2D4 | Q7Z3S7 | 2/20 | 0.53 |
| ▸ | CACNA2D3 | Q8IZS8 | 2/20 | 0.53 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10084685 | 0.99 | CACNB4 (0.52) | CACNA1GCACNB4CACNA1ACACNG3CACNA1F | |
| SCHEMBL10084673 | 0.91 | LMNA (0.49) | CACNA1GCACNB4CACNA1ACACNG3CACNA1F | |
| SCHEMBL10085035 | 0.84 | KDM4E (0.48) | PARGKDM4EKMT2A | |
| SCHEMBL10085524 | 0.82 | KMT2A (0.50) | PARGKDM4EKMT2A | |
| SCHEMBL10085644 | 0.81 | TP53 (0.46) | PARGPLK1KDM4EKMT2A | |
| SCHEMBL10084485 | 0.81 | KMT2A (0.48) | PARGKDM4EPOLBKMT2A | |
| SCHEMBL10084698 | 0.81 | HDAC1 (0.47) | PARGPLK1KDM4EKMT2A | |
| SCHEMBL10084482 | 0.81 | KDM4E (0.57) | PARGNPSR1KDM4EPOLBKMT2A | |
| SCHEMBL10084483 | 0.80 | KMT2A (0.48) | PARGKDM4EKMT2A | |
| SCHEMBL10084712 | 0.79 | KMT2A (0.47) | PARGNPSR1KDM4EPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732078-B2 | Therapeutic use of imidazopyridine derivatives | SANOFI (FR) | 2017-08-15 | — | — | US | disclosed |
| US-9732078-B2 | Therapeutic use of imidazopyridine derivatives | SANOFI (FR) | 2017-08-15 | — | — | US | disclosed |
| US-9452164-B2 | Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof | SANOFI (FR) | 2016-09-27 | — | — | US | disclosed |
| US-9452164-B2 | Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof | SANOFI (FR) | 2016-09-27 | — | — | US | disclosed |
| EP-2800566-B1 | THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES | SANOFI SA (FR) | 2015-10-28 | — | — | EP | disclosed |
| EP-2590976-B1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2015-09-16 | — | — | EP | disclosed |
| US-20140343054-A1 | Therapeutic Use of Imidazopyridine Derivatives | SANOFI (FR) | 2014-11-20 | — | — | US | disclosed |
| US-20140343054-A1 | Therapeutic Use of Imidazopyridine Derivatives | SANOFI (FR) | 2014-11-20 | — | — | US | disclosed |
| US-20140243328-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-08-28 | — | — | US | disclosed |
| US-20140243328-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-08-28 | — | — | US | disclosed |
| US-8759344-B2 | Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-06-24 | — | — | US | disclosed |
| US-8759344-B2 | Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-06-24 | — | — | US | disclosed |
| WO-2013102860-A1 | THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES | SANOFI (FR) | 2013-07-11 | — | — | WO | disclosed |
| US-20130116250-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-09 | — | — | US | disclosed |
| US-20130116250-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-09 | — | — | US | disclosed |
| WO-2012004732-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243328-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CCNY, ENY2, PAH | CACNA1G 4109/4885CACNB4 2911/4885CACNA1A 1657/4885 |
| US-20140343054-A1 | Therapeutic Use of Imidazopyridine Derivatives | CCNY, UTS2R, WNK2 | CACNA1G 2425/4885CACNB4 1357/4885CACNA1A 633/4885 |
| US-20130116250-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CCNY, ENY2, PAH | CACNA1G 4109/4885CACNB4 2911/4885CACNA1A 1657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.